Gracell Biotechnologies Inc.

12.90-0.8900-6.45%Vol 51.37K1Y Perf -47.69%
Apr 16th, 2021 16:00 DELAYED
BID12.91 ASK13.80
Open13.53 Previous Close13.79
Pre-Market- After-Market-
 - -  - -%
Target Price
34.75 
Analyst Rating
— — 0.00
Potential %
169.38 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap845.76M 
Earnings Rating
Price Range Ratio 52W %
2.80 
Earnings Date
-

Today's Price Range

12.9013.63

52W Range

12.3033.70

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-4.44%
1 Month
-44.59%
3 Months
-
6 Months
-
1 Year
-47.69%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GRCL12.90-0.8900-6.45
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume51.37K
Shares Outstanding65.56M
Trades Count790
Dollar Volume1.80M
Avg. Volume147.64K
Avg. Weekly Volume85.35K
Avg. Monthly Volume126.73K
Avg. Quarterly Volume115.21K

Gracell Biotechnologies Inc. (NASDAQ: GRCL) stock closed at 12.9 per share at the end of the most recent trading day (a -6.45% change compared to the prior day closing price) with a volume of 51.37K shares and market capitalization of 845.76M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 160 people. Gracell Biotechnologies Inc. CEO is Wei William Cao.

The one-year performance of Gracell Biotechnologies Inc. stock is -47.69%, while year-to-date (YTD) performance is %. GRCL stock has a five-year performance of %. Its 52-week range is between 12.3 and 33.7, which gives GRCL stock a 52-week price range ratio of 2.80%

Gracell Biotechnologies Inc. currently has a PE ratio of -6.80, a price-to-book (PB) ratio of 37.54, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.64%, a ROC of -37.55% and a ROE of 63.70%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Gracell Biotechnologies Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Gracell Biotechnologies Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Gracell Biotechnologies Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Gracell Biotechnologies Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Gracell Biotechnologies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Gracell Biotechnologies Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 31.62, ATR14 : 0.83, CCI20 : -66.38, Chaikin Money Flow : -0.18, MACD : -2.56, Money Flow Index : 38.67, ROC : -12.24, RSI : 34.18, STOCH (14,3) : 11.15, STOCH RSI : 0.78, UO : 37.90, Williams %R : -88.85), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Gracell Biotechnologies Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfil unmet medical needs in the treatment of cancer.

CEO: Wei William Cao

Telephone: +86 51262626701

Address: 218 Sangtian Street, Suzhou 215123, , CN

Number of employees: 160

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

67%33%

News

Stocktwits